Study of TG-C in Patients With Grade 3 Degenerative Joint Disease of the Knee

Inclusion Criteria: 1. Male or Female subject 2. Age 18 to 70 years 3. In general good health as evidenced by physical examination, normal hematology, serum chemistry, and urinalysis screening laboratory results, and a negative history of significant organ system disorders. All laboratory values must be within 20% of normal ranges. 1. Body Mass Index (BMI) should be between '18.5 - 45.5'. The applied scale is the same for both men and women. 2. Blood Pressure measurements - Systolic Blood Pressure should be between 90-160mm. Hg, and Diastolic Blood Pressure between 50-90mm.Hg, 4. Patients with Grade 3 chronic osteoarthritis of the knee as determined by the Radiographic Criteria of Kellgren and Lawrence. 5. Symptom of pain for more than four (4) consecutive months and intensity of ≥ 40 and ≤ 90 on the 100-mm scale. 6. Patients should be cleared to use protocol specified equipment: 3T MRI. 7. Patients providing written informed consent after the nature of the study is fully explained and understood by the patient. Exclusion Criteria: 1. Age 71 or older 2. Patients with abnormal hematology, serum chemistry, or urinalysis screening laboratory results. 3. Patients taking non-steroidal anti-inflammatory medications within 14 days of baseline visit unless washed out as per section 3.6.4 above. 4. Patients taking steroidal anti-inflammatory medications within 2 months of baseline visit. 5. Patients with a recent (within 1 year) history of drug abuse and/or a positive urine drug test at the time of screening. 6. Patients receiving injections to the treated knee within 2 months prior to study entry 7. Patients who are contraindicated for 3T MRI. 8. Patients who are pregnant or currently breast-feeding children. 9. Patients with systemic, rheumatic or inflammatory disease of the knee or chondrocalcinosis, hemochromatosis, inflammatory arthritis, necrosis of the femoral condyle, arthropathy of the knee associated with juxta-articular Paget's disease of the femur or tibia, ochronosis, hemophilic arthropathy, infectious arthritis, Charcot's knee joint, villonodular synovitis, synovial chondromatosis, and/or history of inflammatory arthropathy. 10. Patients with ongoing infectious disease, including HIV and hepatitis B or C. 11. Patients with clinically significant cardiovascular, renal, hepatic, endocrine disease, cancer, or Type I diabetes. 12. Patients participating in a study of an experimental drug or medical device within 30 days of study entry. 13. Patients that will be unable to comply with the requisite study follow-up and are not able to complete all of the follow-up office visits and 3T MRI exams.